At the news
? NEUTRALIMPACT 4/10 8-K filed Apr 7, 2026 at 16:15 ET
Outlook Therapeutics submitted a formal dispute resolution request to the FDA regarding a Complete Response Letter for its ONS-5010/LYTENAVA biologics license application, and the FDA has accepted the request and granted a meeting with the deciding official. This is a procedural step in the regulatory review process for a drug that was previously not approved.
- Company submitted a Formal Dispute Resolution Request (FDRR) to the FDA regarding a December 30, 2025 Complete Response Letter (CRL) for ONS-5010/LYTENAVA
- FDA accepted the FDRR and granted a meeting with the deciding official to be conducted in April 2026
- The BLA concerns ONS-5010/LYTENAVA for treatment of neovascular age-related macular degeneration
- Company believes existing clinical data from NORSE TWO and NORSE EIGHT trials support approval
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access